English  |  正體中文  |  简体中文  |  Items with full text/Total items : 26988/38789
Visitors : 2357985      Online Users : 49
RC Version 4.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search
LoginUploadHelpAboutAdminister

Please use this identifier to cite or link to this item: http://ntour.ntou.edu.tw:8080/ir/handle/987654321/38401

Title: Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma
Authors: Hou MM
Hsieh JJ
Chang NJ
Huang HY
Wang HM
Chuang CK
Hsu T
Chang JW.
Contributors: 國立臺灣海洋大學:生命科學暨生物科技學系
Date: 2010
Issue Date: 2016-08-31T07:01:57Z
Publisher: Clinical Drug Investigation
Abstract: Abstract: Sorafenib, a multikinase inhibitor of tumour-cell proliferation and angiogenesis, has been shown to have a role in the treatment of metastatic renal cell carcinoma (RCC). Xp11 translocation carcinoma is a rare subtype of RCC. We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment. Six weeks after commencement of treatment with sorafenib, a CT scan of the patient showed increased central necrosis of the kidney mass and para-aortic lymph nodes as well as regression of the lung and pleural masses. The patient had a progression-free survival of 12 months, and overall survival of 15 months. The most severe adverse effects were grade 3 dermatitis and grade 3 anaemia. This case has demonstrated for the first time that sorafenib is active against Xp11 translocation RCC.
Relation: 30(11)
URI: http://ntour.ntou.edu.tw:8080/ir/handle/987654321/38401
Appears in Collections:[生命科學系] 期刊論文

Files in This Item:

File Description SizeFormat
index.html0KbHTML73View/Open


All items in NTOUR are protected by copyright, with all rights reserved.

 


著作權政策宣告: 本網站之內容為國立臺灣海洋大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,請合理使用本網站之內容,以尊重著作權人之權益。
網站維護: 海大圖資處 圖書系統組
DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback